All in the blood: New way to detect drug resistance in ovarian cancer patients

byWalter and Eliza Hall InstituteThe "splicing" mechanism in cancer cells allows them to repair their DNA and avoid the cell death caused by PARP inhibitor therapy, resulting in drug r

Updated on: December 02,2024

All in the blood: New way to detect drug resistance in ovarian cancer patients

byWalter and Eliza Hall InstituteThe "splicing" mechanism in cancer cells allows them to repair their DNA and avoid the cell death caused by PARP inhibitor therapy, resulting in drug r

Updated on:December 02,2024

Tiny, implantable therapeutic sponge device helps kill cancer in mice

by Wayne Lewis,University of California, Los AngelesThe SymphNode device (left), contains nanoparticles (red dots) that release a drug that blocks the activity of regulatory T cells (green), whi

Updated on: January 08,2024

Tiny, implantable therapeutic sponge device helps kill cancer in mice

by Wayne Lewis,University of California, Los AngelesThe SymphNode device (left), contains nanoparticles (red dots) that release a drug that blocks the activity of regulatory T cells (green), whi

Updated on:January 08,2024

Robotic resection cuts perioperative morbidity with liver cancer

by Lori SolomonRobotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), ac

Updated on: December 25,2023

Robotic resection cuts perioperative morbidity with liver cancer

by Lori SolomonRobotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), ac

Updated on:December 25,2023

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024

First map of circular DNA in childhood cancer

byCharité - Universitätsmedizin BerlinDNA of a neuroblastoma cell: Between the chromosomes (blue) there are numerous small DNA rings (green). The centromere of chromosome 2 is stained red. Credi

Updated on: December 22,2023

First map of circular DNA in childhood cancer

byCharité - Universitätsmedizin BerlinDNA of a neuroblastoma cell: Between the chromosomes (blue) there are numerous small DNA rings (green). The centromere of chromosome 2 is stained red. Credi

Updated on:December 22,2023

Quantitative pathologic analysis may help predict prognosis in colorectal cancer

The quantitative segmentation algorithm (QuantCRC) may improve the prediction of prognosis in colorectal cancer (CRC), according to a study published online Aug. 16 inGastroenterology.Reetesh K.

Updated on: December 20,2023

Quantitative pathologic analysis may help predict prognosis in colorectal cancer

The quantitative segmentation algorithm (QuantCRC) may improve the prediction of prognosis in colorectal cancer (CRC), according to a study published online Aug. 16 inGastroenterology.Reetesh K.

Updated on:December 20,2023

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on: December 02,2024

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on:December 02,2024

Lung nodule program provides benefits to patients ineligible for lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainAdopting a lung nodule program (LNP) may increase the detection of early lung cancer for patients who are not

Updated on: December 30,2023

Lung nodule program provides benefits to patients ineligible for lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainAdopting a lung nodule program (LNP) may increase the detection of early lung cancer for patients who are not

Updated on:December 30,2023

Molecular jackhammers drill pathway to killing cancer cells  

JANUARY 19, 2024by Michelle Revels,Texas A&M University College of EngineeringResearchers have developed a technique that employs nanoscopic molecular jackhammers capable of cracking a cell&

Updated on: March 15,2024

Molecular jackhammers drill pathway to killing cancer cells  

JANUARY 19, 2024by Michelle Revels,Texas A&M University College of EngineeringResearchers have developed a technique that employs nanoscopic molecular jackhammers capable of cracking a cell&

Updated on:March 15,2024

Research raises hope for new therapies for chordoma, a rare bone cancer

by Tom Ulrich,Broad Institute of MIT and HarvardCredit: Susanna M. Hamilton, Broad CommunicationsChordoma is literally a one in a million cancer, with few effective treatment options. A new unde

Updated on: May 31,2024

Research raises hope for new therapies for chordoma, a rare bone cancer

by Tom Ulrich,Broad Institute of MIT and HarvardCredit: Susanna M. Hamilton, Broad CommunicationsChordoma is literally a one in a million cancer, with few effective treatment options. A new unde

Updated on:May 31,2024

Quitting smoking tied to better survival in head, neck squamous cell carcinoma

by Lori SolomonSmoking cessation for >10 years is significantly associated with reduced overall mortality and head and neck squamous cell carcinoma (HNSCC)-specific mortality, according to a study

Updated on: December 26,2023

Quitting smoking tied to better survival in head, neck squamous cell carcinoma

by Lori SolomonSmoking cessation for >10 years is significantly associated with reduced overall mortality and head and neck squamous cell carcinoma (HNSCC)-specific mortality, according to a study

Updated on:December 26,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Updated on: December 18,2023

Radiation/cisplatin combination established as standard of care for HPV+ oral cancer

byAmerican Society for Radiation OncologyCombinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial

Updated on:December 18,2023